GSK (GSK) to Release Quarterly Earnings on Wednesday

GSK (NYSE:GSK) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $1.06 per share and revenue of $7.52 billion for the quarter. GSK has set its FY 2025 guidance at 2.090-2.130 EPS.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Stock Performance

NYSE:GSK opened at $36.60 on Wednesday. GSK has a twelve month low of $31.72 and a twelve month high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock has a market cap of $75.51 billion, a P/E ratio of 23.02, a PEG ratio of 1.12 and a beta of 0.56. The business’s 50-day moving average price is $37.44 and its two-hundred day moving average price is $36.06.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were given a $0.3932 dividend. The ex-dividend date was Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.30%. GSK’s payout ratio is 100.63%.

Institutional Trading of GSK

An institutional investor recently bought a new position in GSK stock. Brighton Jones LLC acquired a new position in GSK plc (NYSE:GSK) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 15,604 shares of the pharmaceutical company’s stock, valued at approximately $528,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on GSK. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 16th. BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price objective for the company. Finally, Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Eight research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.